415 Capital

Supira Medical is pleased to share another site has enrolled a patient in our U.S. Early Feasibility Study! A sincere thank you to the entire Montefiore Health System team for their support, and especially site principal investigator Dr. Andrea Mignatti for his collaboration on this study.   The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S.   #pVAD #innovation #medtech #makingadifference Nitin Salunke Nicole Haratani Veronica Neiman

🌟 Exciting times in the world of neurovascular innovation! 🌟 The treatment landscape for neurovascular diseases, including #stroke, is evolving rapidly with groundbreaking new approaches. Yesterday at the BRAIN Conference, we were inspired by insights into the latest advancements in treating Intracranial Atherosclerotic Disease (#ICAD). Today, the excitement continues as we dive into cutting-edge innovations in acute ischemic stroke care—think next-gen aspiration pumps and advanced large-bore aspiration catheters. It’s incredible to see how technology is pushing the boundaries of what's possible for patients. 415 Capital is here to learn and invest alongside so many brilliant minds in the field! 👋 If you’re here at BRAIN, let’s connect. #Neurovascular #Innovation #StrokeTreatment #MedTech Linus Rieder and Ruben Osnabrugge #neurovascular

🧠🎉 415 Capital will be attending the upcoming BRAIN Conference in London! 🧠🎉 Ruben Osnabrugge and Linus Rieder will be representing our team. Both are looking forward to connecting with fellow professionals, sharing insights, and exploring the latest developments in the treatment of neurovascular diseases. At 415 Capital, we are committed to backing life-saving innovation. If you're passionate about the future of healthcare and are interested in learning more about our mission and investment strategy, feel free to reach out. We are excited to see you in London! #BRAINConference #London #VentureCapital #MedTech #415Capital

🦃🍁🍂 Happy Thanksgiving from 415 Capital 🦃🍁🍂 As our American friends are gathering with their loved ones to celebrate Thanksgiving, we'd like to use this opportunity to extend a heartfelt thank you to our incredible community. With your support we've been able to celebrate significant milestones in recent months, each one reflecting our partners' passion and unwavering dedication to improving patient care. A very happy holiday season to you and your loved ones. We are deeply grateful to be on this journey with you! ✨ Read more in our latest Newsletter: 🔗 https://lnkd.in/eEkNDiWk cc: Supira Medical, R3 Vascular Inc., Distalmotion, TRiCares GmbH, Aktiia, Laza Medical, CorFlow, Cardiac Success Ltd.

📢📢📢 Portfolio News: Supira Medical Launches U.S. Early Feasibility Study! We're excited to share that the first U.S. patient has been treated using Supira Medical's transformative low-profile, high-continuous-flow percutaneous ventricular assist device (pVAD) at Piedmont Heart Institute in Atlanta, Georgia. The milestone case was performed under the expert care of Dr. David Kandzari and his team. With over 70 patients treated across South American clinical sites to date, this achievement marks an important step in expanding the clinical evidence base for Supira’s breakthrough technology in the United States. 🍾🍾🍾 Congratulations to the teams at Supira Medical and Shifamed for this remarkable achievement. Your innovation and commitment continue to drive transformative outcomes for patients worldwide! cc: Nitin Salunke, Amr Salahieh

🌟 Kicking off the week with more good news! 📢📢📢: The FDA has granted R3 Vascular Inc. IDE approval for the ELITE-BTK pivotal trial! A major milestone that brings R3's next-generation MAGNITUDE bioresorbable technology one step closer to helping patients suffering from Chronic Limb-Threatening Ischemia due to Peripheral Artery Disease. Led by investigator Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, Director of Vascular Intervention at Beth Israel Deaconess Medical Center, the ELITE-BTK trial will be conducted across up to 60 global clinical sites and involve 264 patients. This achievement is the result of the tireless dedication and countless hours of work by the R3 Vascular team. Congratulations Chris Owens, Kamal Ramzipoor, Josh Smale, Afsoon Fallahi, Chang Lee! cc: Jack Springer, Amir Abolfathi, David Neustaedter, Mike Hurley, MD, MS, Nehan Chatoor, Linus Rieder

🚀🚀🚀 We're excited to share the launch of our new EUR 150M fund—a significant milestone for our firm and a further commitment to our mission of bringing breakthrough, life-saving medical innovation to patients. We are immensely grateful for the trust our limited partners and portfolio companies continue to place in us. We’re also pleased to welcome Azin Parhizgar and Ruben Osnabrugge to our investment committee. Their deep clinical and operational experience is invaluable!

📢📢📢 Portfolio News: De Novo FDA Approval for Distalmotion!!! Congratulations to our portfolio company Distalmotion for securing De Novo FDA approval for its Dexter surgical robot in adult inguinal hernia repair. This approval marks a new era for soft tissue robotics in the US outpatient setting and ambulatory surgery centers. Incredible work by the entire Distalmotion team under the very capable leadership of Greg Roche, Michael Friedrich, Frank Schulkes, Alex Berthoud, Felix Wandel, Chris Rabbitt, Todd Tonsing and with strategic guidance of an all-star board (Rick Anderson, Todd M. Pope, Heinz Jacqui, Martin Dewhurst). 🍾🍾🍾

We're #hiring a new Working Student / Intern (m/f/d) in Munich, Bavaria. Apply today or share this post with your network.

We will be attending the TCT conference in Washington D.C., 26.-31. October! At 415 Capital, we are committed to funding life-saving innovation. Feel free to reach out if you'd like to meet up at the conference. We are excited to see you there! #TCT #WashingtonDC #VentureCapital #MedTech #415Capital Frederik Groenewegen, Azin Parhizgar, PhD, David P. Thompson, Ruben Osnabrugge, Linus Rieder, Michael Braun